M
Michael A. Heneghan
Researcher at University of Cambridge
Publications - 289
Citations - 10869
Michael A. Heneghan is an academic researcher from University of Cambridge. The author has contributed to research in topics: Liver transplantation & Autoimmune hepatitis. The author has an hindex of 51, co-authored 245 publications receiving 9041 citations. Previous affiliations of Michael A. Heneghan include National Health Service & King's College.
Papers
More filters
Journal ArticleDOI
The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility
Lin Lee Wong,Lin Lee Wong,Holly Fisher,Deborah D. Stocken,Stephen Rice,Amardeep Khanna,Amardeep Khanna,Michael A. Heneghan,Ye Htun Oo,George F. Mells,Stuart Kendrick,Jessica K Dyson,Jessica K Dyson,David Jones +13 more
TL;DR: HRQOL, measured by the EQ‐5D‐5L utility index, is shown to be significantly impaired in a large cohort of AIH patients compared with population norms, highlighting the need for better corticosteroid‐free therapy approaches in AIH.
Journal ArticleDOI
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort
Greta Pells,George F. Mells,George F. Mells,Marco Carbone,Marco Carbone,Julia L. Newton,Andrew Bathgate,Andrew K. Burroughs,Michael A. Heneghan,James Neuberger,Darren B. Day,Samantha J. Ducker,Richard Sandford,Graeme J.M. Alexander,David Jones +14 more
TL;DR: No evidence of improved systemic symptoms after liver transplantation in PBC is found and patients should be advised accordingly, and consideration needs to be given to enhancing rehabilitation approaches to improve function and life quality after Liver transplant for PBC.
Journal ArticleDOI
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Jörn M. Schattenberg,Albert Parés,Kris V. Kowdley,Michael A. Heneghan,Stephen H. Caldwell,Daniel Pratt,Alan Bonder,Gideon M. Hirschfield,Cynthia Levy,John M. Vierling,David Jones,Anne Tailleux,Bart Staels,S. Megnien,Rémy Hanf,David Magrez,Pascal Birman,Velimir A. Luketic +17 more
TL;DR: Elafibranor is a dual PPARα/δ agonist that was tested in a randomized clinical trial over 12 weeks in patients with primary biliary cholangitis.
Journal ArticleDOI
Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?
TL;DR: The aim of this review is to better characterize this subset of patients; to differentiate them clinically, serologically, and histologically from chronic AIH and other causes of acute liver failure; and to present the role, predictors, and optimal timings of corticosteroid therapy and LT.
Journal ArticleDOI
Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis.
Tiong Yeng Lim,Marc Martinez-Llordella,Elisavet Kodela,Elisabeth Gray,Michael A. Heneghan,Alberto Sanchez-Fueyo +5 more
TL;DR: The clinical and immunological effects of LDIL-2 in 2 patients with refractory AIH are reported, and the use of lowdose IL-2 (LDIL- 2) as an immunomodulatory agent is being explored in various autoimmune disorders.